Dr. Andrew Place, MD, PhD
Claim this profileDana-Farber Cancer Institute
Studies T-Lymphoblastic Leukemia/Lymphoma
Studies Acute Lymphoblastic Leukemia
11 reported clinical trials
26 drugs studied
Area of expertise
1T-Lymphoblastic Leukemia/Lymphoma
BCR-ABL1 positive
Stage IV
BCR-ABL1 T315I positive
2Acute Lymphoblastic Leukemia
BCR-ABL1 positive
Stage IV
BCR-ABL1 T315I positive
Affiliated Hospitals
Clinical Trials Andrew Place, MD, PhD is currently running
Venetoclax Combination Therapy
for Blood Cancers
This trial is evaluating the safety and tolerability of venetoclax with chemotherapy in pediatric and young adult patients with hematologic malignancies, including myelodysplastic syndrome (MDS), acute myeloid leukemia derived from myelodysplastic syndrome (MDS/AML), and acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LBL). The names of the study drugs involved in this study are below. Please note this is a list for the study as a whole, participants will receive drugs according to disease cohort. * Venetoclax * Azacitidine * Cytarabine * Methotrexate * Hydrocortisone * Leucovorin * Dexamethasone * Vincristine * Doxorubicin * Dexrazoxane * Calaspargase pegol * Hydrocortisone
Recruiting1 award Phase 1
Tagraxofusp
for Blood Cancers
Tagraxofusp is a protein-drug conjugate consisting of a diphtheria toxin redirected to target CD123 has been approved for treatment in pediatric and adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). This trial aims to examine the safety of this novel agent in pediatric patients with relapsed/refractory hematologic malignancies. The mechanism by which tagraxofusp kills cells is distinct from that of conventional chemotherapy. Tagraxofusp directly targets CD123 that is present on tumor cells, but is expressed at lower or levels or absent on normal hematopoietic stem cells. Tagraxofusp also utilizes a payload that is not cell cycle dependent, making it effective against both highly proliferative tumor cells and also quiescent tumor cells. The rationale for clinical development of tagraxofusp for pediatric patients with hematologic malignancies is based on the ubiquitous and high expression of CD123 on many of these diseases, as well as the highly potent preclinical activity and robust clinical responsiveness in adults observed to date. This trial includes two parts: a monotherapy phase and a combination chemotherapy phase. This design will provide further monotherapy safety data and confirm the FDA approved pediatric dose, as well as provide safety data when combined with chemotherapy. The goal of this study is to improve survival rates in children and young adults with relapsed hematological malignancies, determine the recommended phase 2 dose (RP2D) of tagraxofusp given alone and in combination with chemotherapy, as well as to describe the toxicities, pharmacokinetics, and pharmacodynamic properties of tagraxofusp in pediatric patients. About 54 children and young adults will participate in this study. Patients with Down syndrome will be included in part 1 of the study.
Recruiting1 award Phase 1
More about Andrew Place, MD, PhD
Clinical Trial Related6 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Andrew Place, MD, PhD has experience with
- Cytarabine
- Dexamethasone
- Methotrexate
- Venetoclax
- Fludarabine
- Oncaspar
Breakdown of trials Andrew Place, MD, PhD has run
T-Lymphoblastic Leukemia/Lymphoma
Acute Lymphoblastic Leukemia
Lymphoid Leukemia
Acute Myeloid Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Andrew Place, MD, PhD specialize in?
Andrew Place, MD, PhD focuses on T-Lymphoblastic Leukemia/Lymphoma and Acute Lymphoblastic Leukemia. In particular, much of their work with T-Lymphoblastic Leukemia/Lymphoma has involved BCR-ABL1 positive patients, or patients who are Stage IV.
Is Andrew Place, MD, PhD currently recruiting for clinical trials?
Yes, Andrew Place, MD, PhD is currently recruiting for 2 clinical trials in Boston Massachusetts. If you're interested in participating, you should apply.
Are there any treatments that Andrew Place, MD, PhD has studied deeply?
Yes, Andrew Place, MD, PhD has studied treatments such as Cytarabine, Dexamethasone, Methotrexate.
What is the best way to schedule an appointment with Andrew Place, MD, PhD?
Apply for one of the trials that Andrew Place, MD, PhD is conducting.
What is the office address of Andrew Place, MD, PhD?
The office of Andrew Place, MD, PhD is located at: Dana-Farber Cancer Institute, Boston, Massachusetts 02215 United States. This is the address for their practice at the Dana-Farber Cancer Institute.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.